Skip to content

    Hepatitis Health Center

    Font Size

    New Drug Combo Helps Hard-to-Treat Hepatitis C

    NIH study focused largely on black patients, who haven't fared as well with current treatments


    "We're in the middle of an exciting time," Schiff said. "I'm very optimistic."

    The current study included 60 hepatitis C patients with factors that make standard interferon-based treatment unlikely to work.

    Most had a genetic strain of the virus that does not respond well to interferon. Many also had liver fibrosis -- scarring of the organ that can progress to more severe damage, known as cirrhosis, and possibly liver cancer. And most participants were black, a group that traditionally has not fared as well with hepatitis C regimens compared to whites.

    All of the patients were given sofosbuvir, an oral drug, plus either low-dose ribavirin or a dose adjusted to their weight. After 24 weeks of treatment, 68 percent of those given the weight-based ribavirin had a "sustained virologic response," which equates to a cure, Schiff said.

    Of the patients in the low-dose group, 48 percent were cured.

    Headache, anemia, fatigue and nausea were the most common side effects, affecting anywhere from 16 percent to 33 percent of the patients. But none dropped out of treatment due to side effects, the researchers said.

    Fauci agreed that drug regimens that bypass both interferon and ribavirin are the wave of the future. "The ultimate goal is to have a drug combination that would be nontoxic and have a high cure rate," he said.

    The drugs under development also are expected to cut the treatment time from up to 48 weeks to 12 weeks or less, Schiff said.

    More than 3 million Americans are living with chronic hepatitis C, but most don't know it, Fauci said. "That's why there's a big push for screening," he said.

    U.S health officials recommend that all baby boomers (people born from 1945 to 1965) get tested for chronic hepatitis C infection. The virus is mainly transmitted through infected blood, and injection-drug use is the top risk factor. But people who had a blood transfusion before 1992 also are at risk, because that predated widespread screening for hepatitis C.

    In a small number of cases, the virus is passed during sex.

    Today on WebMD

    Hepatitus C virus
    Types, symptoms and treatments.
    liver illustration
    Myths and facts about this essential organ.
    woman eating apple
    What you need to know.
    doctor and patient
    What causes it?
    Hepatitis C Treatment
    Syringes and graph illustration
    liver illustration
    passport, pills and vaccine
    Scientist looking in microscope
    Fatty Liver Disease
    Digestive Diseases Liver Transplantation
    Picture Of The Liver
    Image Collection